Background The use of quinolone prophylaxis in high-risk neutropenic patients is considered standard of care but the development of resistance is a concern. Previous studies have focused mainly on ...
Although most experts advise that such patients receive CMV prophylaxis, CMV disease often develops shortly after stopping a 3-month course of antiviral prophylaxis (often between 3 and 6 months ...